Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2021

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and six months ended June 30, 2021 and 2020 as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Product revenue:
Instruments	$	397,205	$	257,029	$	621,218	$	491,654
Consumables		867,970		781,304		1,472,352		1,327,243
Total product revenue		1,265,175		1,038,333		2,093,570		1,818,897
Product-related services revenue:
Custom RUO assay design		—		343,284		48,350		972,466
RUO sample processing		809,029		346,909		1,367,430		925,300
Total product-related services revenue		809,029		690,193		1,415,780		1,897,766
Total product and product-related services revenue	$	2,074,204	$	1,728,526	$	3,509,350	$	3,716,663

Schedule of Collaborative Development Services

Collaborative Development Services Revenue

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. For the three and six months ended June 30, 2020, collaborative development services revenue was generated through statements of work entered into a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”) discussed below.  

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Collaborative development services	$	—	$	234,768	$	—	$	472,105

Schedule of Changes in Contract Liability

Changes in the Company’s contract liability were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design		Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	-	$	93,884		$	197,464
Deferral of revenue		153,400			—		350,224			503,624
Recognition of deferred revenue		(130,759	)		—		(351,626	)		(482,385	)
Balance at June 30, 2021	$	126,221		$	—	$	92,482		$	218,703

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		273,829			337,035			67,729			678,593
Recognition of deferred revenue		(272,653	)		(403,251	)		(55,971	)		(731,875	)
Balance at June 30, 2020	$	96,324		$	—		$	449,848		$	546,172